Drugs · acquisition-cost intelligence
Mesalamine
· ingredient mesalamine· MESALAMINE 4 g/60mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$0.18388
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 7 weeks.
2025-03-192026-05-20
Same-ingredient options by acquisition cost
Other mesalamine products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.
| Product | NADAC / ML | vs this |
|---|---|---|
| APRISO | $0.48846 | +$0.30460 |
| Lialda | $0.85594 | +$0.67210 |
| Canasa | $1.36 | +$1.18 |
| Mesalamine | $2.41 | +$2.22 |
| Pentasa | $4.37 | +$4.18 |
| mesalamine | $4.51 | +$4.32 |
Medicare Part D coverage · CY2026
On 287 plan formularies · typical tier 4
Prior auth 0% · Step therapy 0% · Quantity limit 36% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.